Skip to main content

Table 1 Patient and disease baseline characteristics for premenopausal patients in the MONARCH 2 trial

From: Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial

 

Abemaciclib + fulvestrant

N = 72

Placebo + fulvestrant

N = 42

Median age (range)

46 (32–57)

47 (32–66)

Race, n (%)

 Asian

51 (70.8)

24 (57.1)

 Caucasian

14 (19.4)

16 (38.1)

 Other

7 (9.7)

2 (4.8)

Most recent ET, n (%)a

 Neoadjuvant or adjuvant

44 (61.1)

21 (50.0)

 Metastatic

26 (36.1)

20 (47.6)

Number of lines of ET, n (%)

 1

60 (83.3)

30 (71.4)

 2

10 (13.9)

11 (26.2)

Prior AI, n (%)

 Yes

10 (13.9)

12 (28.6)

 No

62 (86.1)

30 (71.4)

Sensitivity to ET, n (%)a

 Primary resistanceb

28 (38.9)

15 (35.7)

 Secondary resistancec

42 (58.3)

26 (61.9)

Progesterone-receptor status, n (%)

 Positive

54 (75.0)

38 (90.5)

 Negative

18 (25.0)

4 (9.5)

Metastatic site, n (%)

 Visceral

43 (59.7)

17 (40.5)

 Bone only

19 (26.4)

15 (35.7)

 Other

10 (13.9)

10 (23.8)

Measurable disease, n (%)

 Yes

51 (70.8)

28 (66.7)

 No

21 (29.2)

14 (33.3)

ECOG performance status

 0

54 (75.0)

36 (85.7)

 1

18 (25.0)

6 (14.3)

  1. AI, aromatase inhibitor; ECOG, Eastern Cooperative Oncology Group; ET, endocrine therapy
  2. aTwo patients in the abemaciclib arm and one patient in the placebo arm received no prior ET; bPatients whose disease relapsed ≤ 2 years while receiving (neo) adjuvant ET or progressed ≤ 6 months of receiving ET for ABC; cPatients receiving prior ET who do not meet the definition of primary resistance were considered to have secondary resistance